A BILL 
To amend the Federal Food, Drug, and Cosmetic Act to 
establish additional authorities of the Food and Drug 
Administration regarding the conduct of pediatric inves-
tigations of molecularly targeted drugs to treat cancer, 
and for other purposes. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Give Kids a Chance 
4
Act of 2022’’. 
5
00:38 Mar 10, 2022
H6972
2 
•HR 6972 IH
SEC. 2. RESEARCH INTO PEDIATRIC USES OF DRUGS; ADDI-
1
TIONAL AUTHORITIES OF FOOD AND DRUG 
2
ADMINISTRATION 
REGARDING 
MOLECU-
3
LARLY TARGETED CANCER DRUGS. 
4
(a) IN GENERAL.— 
5
(1) AUTHORITY REGARDING INVESTIGATION OF 
6
NOVEL
COMBINATION
DRUGS.—Section 
7
505B(a)(1)(B) of the Federal Food, Drug, and Cos-
8
metic Act (21 U.S.C. 355c(a)(1)(B)) is amended, in 
9
the matter preceding clause (i), by inserting after 
10
‘‘Public Health Service Act,’’ the following: ‘‘or an 
11
application under such section 505 or such section 
12
351 for a drug or biological product that contains a 
13
novel combination of two or more active ingredients 
14
(subject to paragraph (3)(B)(iii))’’. 
15
(2) ADDITIONAL ACTIVE INGREDIENT FOR AP-
16
PLICATION DRUG; LIMITATION REGARDING NOVEL- 
17
COMBINATION
APPLICATION
DRUG.—Section 
18
505B(a)(3) of the Federal Food, Drug, and Cos-
19
metic Act (21 U.S.C. 355c(a)(3)) is amended— 
20
(A) by redesignating subparagraphs (B) 
21
and (C) as subparagraphs (C) and (D), respec-
22
tively; and 
23
(B) by striking subparagraph (A) and in-
24
serting the following: 
25
00:38 Mar 10, 2022
H6972
3 
•HR 6972 IH
‘‘(A) IN GENERAL.—For purposes of para-
1
graph (1)(B), the investigation described in this 
2
paragraph is (as determined by the Secretary) 
3
a molecularly targeted pediatric cancer inves-
4
tigation of— 
5
‘‘(i) the drug or biological product for 
6
which the application referred to in such 
7
paragraph is submitted; or 
8
‘‘(ii) the active ingredient or ingredi-
9
ents of such drug or biological product in 
10
combination with— 
11
‘‘(I) an active ingredient of a 
12
drug for which an approved applica-
13
tion under section 505(j) is in effect 
14
or an active ingredient of a biological 
15
product for which an approved appli-
16
cation under section 351(k) of the 
17
Public Health Service Act is in effect, 
18
which drug or biological product is de-
19
termined by the Secretary to be the 
20
standard of care for treating a pedi-
21
atric cancer; 
22
‘‘(II) an active ingredient of a 
23
drug for which an approved applica-
24
tion under section 505(b) is in effect 
25
00:38 Mar 10, 2022
H6972
4 
•HR 6972 IH
to treat an adult cancer, or an active 
1
ingredient of a biological product for 
2
which an approved application under 
3
section 351(a) of the Public Health 
4
Service Act is in effect to treat an 
5
adult cancer, which approved applica-
6
tion is held by the same person sub-
7
mitting the application referred to in 
8
paragraph (1)(B); or 
9
‘‘(III) an active ingredient of a 
10
drug or biological product for which 
11
there is in effect an exemption for in-
12
vestigational use under section 505(i), 
13
which drug or biological product is 
14
under such exemption being studied 
15
jointly by the person submitting the 
16
application referred to in paragraph 
17
(1)(B) and by another person pursu-
18
ant to an agreement between such 
19
persons. 
20
‘‘(B) ADDITIONAL REQUIREMENTS.— 
21
‘‘(i) DESIGN
OF
INVESTIGATION.—A 
22
molecularly targeted pediatric cancer inves-
23
tigation referred to in subparagraph (A) 
24
shall be designed to yield clinically mean-
25
00:38 Mar 10, 2022
H6972
5 
•HR 6972 IH
ingful pediatric study data, gathered using 
1
appropriate formulations for each age 
2
group for which the study is required, re-
3
garding dosing, safety, and preliminary ef-
4
ficacy. 
5
‘‘(ii) PURPOSE OF INVESTIGATION.— 
6
The purpose of a molecularly targeted pe-
7
diatric cancer investigation referred to in 
8
subparagraph (A) shall be— 
9
‘‘(I) in the case of such an inves-
10
tigation conducted with respect to a 
11
drug or biological product referred to 
12
in clause (i) of such subparagraph, to 
13
inform potential pediatric labeling of 
14
the drug or biological product for 
15
which the application referred to in 
16
paragraph (1)(B) is submitted; and 
17
‘‘(II) in the case of such an in-
18
vestigation conducted with respect to 
19
a combination of active ingredients 
20
described to in clause (ii) of such sub-
21
paragraph, to assist in determining 
22
the relevance of its molecular target 
23
to the growth or progression of a pe-
24
diatric cancer. 
25
00:38 Mar 10, 2022
H6972
6 
•HR 6972 IH
‘‘(iii) LIMITATION REGARDING INVES-
1
TIGATION OF NOVEL COMBINATION.—For 
2
purposes of paragraph (1)(B), a novel 
3
combination is a combination of two or 
4
more active ingredients for which an appli-
5
cation under section 505 of this Act or sec-
6
tion 351 of the Public Health Service Act 
7
for such combination has not previously 
8
been approved. A pediatric investigation 
9
under this paragraph of such novel com-
10
bination is required only if each of the ac-
11
tive ingredients in the combination has 
12
been approved under such section 505 or 
13
such section 351 to treat an adult cancer. 
14
‘‘(iv) PRECLINICAL DATA.—The Sec-
15
retary may require that reports on an in-
16
vestigation required pursuant to paragraph 
17
(1)(B) shall include the results of all pre-
18
clinical studies on which the decision to 
19
conduct such investigation was based. 
20
‘‘(v) RULE
OF
CONSTRUCTION
RE-
21
GARDING
INACTIVE
INGREDIENTS.—With 
22
respect to a combination of active ingredi-
23
ents referred to in subparagraph (A)(ii), 
24
such subparagraph may not be construed 
25
00:38 Mar 10, 2022
H6972
7 
•HR 6972 IH
as addressing the use of inactive ingredi-
1
ents with such combination.’’. 
2
(3) CLARIFYING
APPLICABILITY
OF
CERTAIN 
3
PROVISIONS.—Section 505B(a)(3) of the Federal 
4
Food, 
Drug, 
and 
Cosmetic 
Act 
(21 
U.S.C. 
5
355c(a)(3)), as amended by paragraph (2), is fur-
6
ther amended by adding at the end the following: 
7
‘‘(E) INTERNAL COMMITTEE REVIEW; LA-
8
BELING CHANGES; DISSEMINATION OF INFOR-
9
MATION; ADVERSE EVENTS; SCOPE OF AUTHOR-
10
ITY.—Subsections (f) through (j) shall apply 
11
with respect to investigations described in this 
12
paragraph to the same extent and in the same 
13
manner as such subsections apply with respect 
14
to the assessments required under paragraph 
15
(1)(A), except that subsection (g) does not 
16
apply with respect to an investigation referred 
17
to in subparagraph (A)(ii) of this paragraph.’’. 
18
(4) 
CONFORMING
AMENDMENTS.—Section 
19
505B(a) of the Federal Food, Drug, and Cosmetic 
20
Act (21 U.S.C. 355c(a)) is amended— 
21
(A) in paragraph (3)(C), as redesignated 
22
by paragraph (2)(A) of this subsection, by 
23
striking ‘‘investigations described in this para-
24
00:38 Mar 10, 2022
H6972
8 
•HR 6972 IH
graph’’ and inserting ‘‘investigations referred to 
1
in subparagraph (A)(i)’’; 
2
(B) in paragraph (3)(D), as redesignated 
3
by paragraph (2)(A) of this subsection, by 
4
striking ‘‘the assessments under paragraph 
5
(2)(B)’’ and inserting ‘‘the assessments re-
6
quired under paragraph (1)(A)’’; and 
7
(C) in paragraph (5)(D), by inserting be-
8
fore the period at the end the following: ‘‘, ex-
9
cept this subparagraph is not applicable to an 
10
investigation 
referred 
to 
in 
paragraph 
11
(3)(A)(ii)’’. 
12
(b) AUTHORITY REGARDING PRECLINICAL STUD-
13
IES.—Section 505B(a)(1) of the Federal Food, Drug, and 
14
Cosmetic Act (21 U.S.C. 355c(a)(1)), as amended by sub-
15
section (a)(1), is further amended by adding at the end 
16
the following: 
17
‘‘(C) 
PRECLINICAL
STUDIES
GEN-
18
ERALLY.— 
19
‘‘(i) IN GENERAL.—With respect to an 
20
application for an exemption for investiga-
21
tional use under section 505(i) for a drug 
22
or biological product that is intended for 
23
the treatment of an adult cancer, the Sec-
24
retary may require, as a condition of per-
25
00:38 Mar 10, 2022
H6972
9 
•HR 6972 IH
mitting the exemption to go into effect, 
1
that the sponsor involved enter into an 
2
agreement with the Secretary to conduct 
3
not more than two preclinical studies of 
4
the drug or biological product in order to 
5
assist in determining the relevance of its 
6
molecular target to the growth or progres-
7
sion of a pediatric cancer. 
8
‘‘(ii) TIMEFRAME
FOR
PRECLINICAL 
9
STUDIES.—With respect to the drug or bi-
10
ological product involved, an agreement 
11
under clause (i) for a preclinical study 
12
shall specify the date by which an initial 
13
plan for the study will be submitted to the 
14
Secretary except that the Secretary may 
15
not require the submission of such plan 
16
any earlier than one year after the exemp-
17
tion referred to in clause (i) goes into ef-
18
fect. The results of the preclinical study 
19
shall be submitted to the Secretary in ac-
20
cordance with a timeframe to which the 
21
Secretary and the sponsor involved have 
22
agreed. Such timeframe shall provide for 
23
deferrals equivalent to deferrals under 
24
paragraph (4).’’. 
25
00:38 Mar 10, 2022
H6972
10 
•HR 6972 IH
(c) APPLICABILITY.—The amendments made by this 
1
section apply with respect to any application under section 
2
505(i) of the Federal Food, Drug, and Cosmetic Act (21 
3
U.S.C. 355(i)), any application under section 505 of such 
4
Act (21 U.S.C. 355), and any application under section 
5
351(a) of the Public Health Service Act (42 U.S.C. 262), 
6
that is submitted on or after the expiration of the 3-year 
7
period beginning on the date of the enactment of this Act. 
8
Æ 
00:38 Mar 10, 2022
H6972
